Alliance Global Partners lowered the firm’s price target on INmune Bio (INMB) to $7 from $20 and keeps a Buy rating on the shares after the company reported topline Phase 2 data from the MINDful trial of XPro for Alzheimer’s disease that “were not what we had hoped for.” The firm adjusted its price target to account for the added uncertainly around the future development for XPro and the additional time that will be needed to find a partner and start confirmatory trials, noting that it now values XPro for Alzheimer’s at $3 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio price target lowered to $8 from $30 at Maxim
- INmune Bio downgraded to Underperform from Outperform at Scotiabank
- INmune Bio downgraded to Neutral from Buy at BTIG
- Inmune Bio’s Xpro Alzheimer’s Trial Faces Challenges, Justifying Hold Rating
- Inmune Bio Secures $18.9 Million in Stock Offering